AIM Vaccine Co Ltd
06660
Company Profile
Business description
AIM Vaccine Co Ltd is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain, ranging from research and development to manufacturing and commercialization. The Vaccine products include Recombinant HBV Vaccines, Freeze-dried Human Rabies Vaccine, Inactivated HAV Vaccines, Group A, C, Y, and W135 MPSV, Bivalent Inactivated HFRS Vaccine, and Mumps Vaccine. It generates the majority of its revenues in the PRC.
Contact
2 Ronghua South Road
26th Floor, Building T6, Han’s Plaza
Economic Technological Development Area
Beijing
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,493
Stocks News & Analysis
stocks
Are declining Chinese births a red flag for A2 Milk?
Demographic challenges in A2’s largest market lead to sell-off.
stocks
Is this ASX share a value trap or bargain?
Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,108.60 | 16.20 | 0.18% |
| CAC 40 | 8,030.58 | 32.00 | -0.40% |
| DAX 40 | 24,432.96 | 270.16 | -1.09% |
| Dow JONES (US) | 48,488.59 | 870.74 | -1.76% |
| FTSE 100 | 10,103.89 | 22.89 | -0.23% |
| HKSE | 26,585.06 | 97.55 | 0.37% |
| NASDAQ | 22,954.32 | 561.07 | -2.39% |
| Nikkei 225 | 52,774.64 | 216.46 | -0.41% |
| NZX 50 Index | 13,417.17 | 156.76 | -1.15% |
| S&P 500 | 6,796.86 | 143.15 | -2.06% |
| S&P/ASX 200 | 8,782.90 | 14.00 | 0.16% |
| SSE Composite Index | 4,116.94 | 3.29 | 0.08% |